Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2024, with a specific reporting date of June 12, 2024. The document serves as a transaction notification under Rule 13a-16 or 15d-16, detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2024-06-11 | Ordinary Shares (31½ pence each) | £16.2324 | 118 Shares (Aggregated) | London Stock Exchange (XLON) |
Note: The total volume of 118 shares is derived from the sum of individual transactions listed for eight executives.
Material Changes
This filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It is a regulatory disclosure of insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are routine acquisitions under the Share Reward Plan, consisting of partnership shares and matching shares.
Important Facts for Investors
- Executive Participation: Eight senior executives, including CEO Emma Walmsley and CFO Julie Brown, acquired shares on June 11, 2024.
- Transaction Type: All transactions were acquisitions under the Company's Share Reward Plan, not open market purchases.
- Share Price: The acquisition price was uniform at £16.2324 per share for all listed transactions.
- Volume: Individual acquisitions ranged from 14 to 16 shares per executive.
- Financial Data: No revenue, earnings, or balance sheet data is present in this specific filing.